

MSK Levels of Evidence



Level 1

FDA-recognized biomarker predictive of response to an **FDA-approved** drug **in this indication**

Level 2A

Standard of care biomarker predictive of response to an **FDA-approved** drug **in this indication***

Level 2B

Standard of care biomarker predictive of response to an **FDA-approved** drug **in another indication**, but not standard of care for this indication

Level 3A

Compelling clinical evidence supports the biomarker as being predictive of response to a drug in this indication, but neither biomarker nor drug are standard of care

Level 3B

Compelling clinical evidence supports the biomarker as being predictive of response to a drug in another indication, but neither biomarker nor drug are standard of care

Level

Compelling biological evidence supports the biomarker as being predictive of response to a drug, but neither biomarker nor drug are standard of care

Standard Therapeutic Implications

*Includes biomarkers
that are recommended
as standard of care
by the NCCN or
other expert panels
but not necessarily
FDA-recognized
for a particular
indication

Investigational
Therapeutic
Implications
possibly directed
to clinical trials

Hypothetical
Therapeutic
Implications
based on
preliminary, nonclincial data

Level R1 **Standard of care** biomarker predictive of **resistance** to an **FDA-approved** drug **in this indication**

Standard Therapeutic Implications